Research Paper Volume 15, Issue 19 pp 10732—10745

Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption

class="figure-viewer-img"

Figure 1. Micheliolide protected mice from OVX induced bone loss. Fifteen wild type female C57/BL6 mice aged 8 weeks were obtained and randomly split into three groups (n=5): Sham group (with Sham surgery and following with vehicle treatment), OVX group (with OVX surgery following with vehicle treatment), MCL group (with OVX operation following with Micheliolide treatment (30 mg/kg/day)). (A) Representative 3D micro-CT images of proximal femur. Scale bar = 500 μm. (BG) Micro-CT values of BMD (mg HA/ccm), BV/TV (%), SMI, Tb.N (1/mm), Tb.Th (mm), and Tb.Sp (mm) were analyzed using the built-in software. (H) Representative Von Kossa staining of the histomorphological sections from each indicated group. (IL) BV/TV, Tb.Th, Tb.N, and Tb.Sp of the Von Kossa staining sections from each group. All data: mean ± SD, n=5, *p < 0.05 comparing to Sham group, **p < 0.01 comparing to Sham group, # p < 0.05 comparing to Sham group, ## p < 0.01 comparing to Sham group.